Quarterly Result14 Aug 2025, 02:12 pm
AstraZeneca Pharma India Sustains Growth Momentum in Q1 FY25-26, Advancing Performance Across Diverse Therapies
AI Summary
AstraZeneca Pharma India Limited announced its financial results for the quarter ended June 30, 2025. The company reported a revenue increase of 36% compared to the same period last year, supported by strategic execution, regulatory milestones, and continued portfolio expansion. The total revenue from operation was 5263.1 INR Mn, with a profit before exceptional item and tax of 750.6 INR Mn, and a profit after exceptional item and tax of 558.3 INR Mn.
Key Highlights
- Revenue rises 36% in Q1 2025-26
- Four new approvals reinforce leadership in Oncology
- Strong Q1 performance reflects the power of science-led innovation combined with disciplined execution
- Expanding portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most